Turing Pharmaceuticals, a months-old biotech startup that is largely financed by its 32-year-old founder and CEO Martin Shkreli, sparked widespread outrage last month. The reason: shortly after paying $55 million for a 62-year-old drug called Daraprim that’s prescribed for toxoplasmosis and other types of infections, Turing repriced the drug from $13.50 per pill to a stunning $750… Read More...